[Skip to Content]
[Skip to Content Landing]
Article
July 1988

Resolution of Cutaneous Lesions of Granuloma Annulare by Intralesional Injection of Human Fibroblast Interferon

Author Affiliations

Department of Dermatology Institute of Clinical Medicine University of Tsukuba Tsukuba-shi, Ibaraki-ken 305, Japan

Arch Dermatol. 1988;124(7):1015-1016. doi:10.1001/archderm.1988.01670070017009
Abstract

To the Editor.—  We report a successful clinical trial of interferon beta-1 for the treatment of granuloma annulare. Although the cause of granuloma annulare still remains unknown, by histochemical and electron microscopic studies, Umbert and Winkelmann1 have observed activated macrophages in the lesion and have presumed that activation of mononuclear phagocytes may be the central event in an inflammatory process of granuloma annulare. Lee and Epstein2 report that interferon beta inhibits maturation of monocytes to macrophages, and we found that interferon beta inhibited activation of monocytes.3 These findings prompted us to study the effect of interferon beta on granuloma annulare.Human interferon beta-1 was a product of human fibroblasts stimulated with Poly I:C.Since human serum albumin was added, as a stabilizer, into a vial of interferon beta-1, a placebo vial, which contained only the same amount of human serum albumin, was also prepared (Toray Industries, Tokyo). A vial of interferon beta-1 was

First Page Preview View Large
First page PDF preview
First page PDF preview
×